Effects of price cap regulation on the pharmaceutical supply chain

Abstract This paper considers a pharmaceutical supply chain composed of one pharmaceutical manufacturer and one pharmacy. We investigate how price cap regulation affects pharmaceutical firms' pricing decisions. We also evaluate the economic and social performance of the pharmaceutical supply chain and assess the risks associated with price cap regulation. The derived equilibriums under different price cap regulations, including retailer price cap regulation, manufacturer price cap regulation and linkage price cap regulation, are compared to that without regulation. Our results show that one-sided price cap regulation will damage the economic performance of the regulated firm, whereas the unregulated firm may gain a financial advantage. The regulation may increase the risk of a supply shortage if pharmaceutical firms cannot cope with the financial loss. In contrast, linkage price cap regulation can be an effective policy for improving both the economic and social performance of the pharmaceutical supply chain.

[1]  A. J. Cullen,et al.  Critical success factors for B2B e‐commerce use within the UK NHS pharmaceutical supply chain , 2009 .

[2]  Andrea Vinelli,et al.  Sequences of improvement in supply networks: case studies from the pharmaceutical industry , 2006 .

[3]  T. Abbott.  Price regulation in the pharmaceutical industry: prescription or placebo? , 1995, Journal of health economics.

[4]  J. Puig-Junoy.  Impact of European Pharmaceutical Price Regulation on Generic Price Competition , 2012, PharmacoEconomics.

[5]  Liz Breen,et al.  Greening community pharmaceutical supply chain in UK: a cross boundary approach , 2012 .

[6]  J. Amankwah‐Amoah.  An integrative process model of organisational failure , 2016 .

[7]  R. Staelin,et al.  Vertical Strategic Interaction: Implications for Channel Pricing Strategy , 1997 .

[8]  R. Myerson,et al.  Regulating a Monopolist with Unknown Costs , 1982 .

[9]  L. Lynd,et al.  The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms , 2016, Medical care.

[10]  Richard J. Fairchild,et al.  Customer, regulatory, and competitive pressure as drivers of environmental innovation , 2011 .

[11]  Hui Zhao,et al.  Fee-for-Service Contracts in Pharmaceutical Distribution Supply Chains: Design, Analysis, and Management , 2012, Manuf. Serv. Oper. Manag..

[12]  Yu Fang,et al.  Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study , 2016, PloS one.

[13]  R. Uthayakumar,et al.  Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital , 2013 .

[14]  Helle Håkonsen,et al.  Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004? , 2009, Health policy.

[15]  A. Krasnikov,et al.  The Effect of Price Regulation on Innovation in the Pharmaceutical Industry , 2011 .

[16]  Xuan Yu,et al.  Pharmaceutical supply chain in China: current issues and implications for health system reform. , 2010, Health policy.

[17]  R. K. Pati,et al.  Managerial research on the pharmaceutical supply chain - A critical review and some insights for future directions , 2014 .

[18]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[19]  Christian L. Rossetti,et al.  Forces, trends, and decisions in pharmaceutical supply chain management , 2011 .

[20]  Vibha Gaba,et al.  A Comparison of Milestone-Based and Buyout Options Contracts for Coordinating R&D Partnerships , 2015, Manag. Sci..

[21]  Salma Karray,et al.  Channel coordination with quantity discounts and/or cooperative advertising , 2016 .

[22]  Klaus Reinholdt Nyhuus Hansen,et al.  Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains , 2015 .

[23]  Jun Zhang,et al.  Impacts of Power Structure on Supply Chains with Uncertain Demand , 2013 .

[24]  Huigang Liang,et al.  Can Price Controls Reduce Pharmaceutical Expenses? A Case Study of Antibacterial Expenditures in 12 Chinese Hospitals from 1996 to 2005 , 2013, International journal of health services : planning, administration, evaluation.

[25]  Ruiqing Zhao,et al.  Impact of price cap regulation on supply chain contracting between two monopolists , 2016 .

[26]  Xu Chen,et al.  Free or bundled: channel selection decisions under different power structures , 2015 .

[27]  Kurt R. Brekke,et al.  Reference Pricing of Pharmaceuticals , 2006, Journal of health economics.

[28]  David D. Dobrzykowski,et al.  A structured analysis of operations and supply chain management research in healthcare (1982–2011) , 2014 .

[29]  Xiaojun Wang,et al.  Effects of carbon emission reduction policies on transportation mode selections with stochastic demand , 2016 .

[30]  S. Ali Torabi,et al.  A robust possibilistic programming approach for pharmaceutical supply chain network design , 2015, Comput. Chem. Eng..

[31]  Xu Chen,et al.  Optimal pricing policies for differentiated brands under different supply chain power structures , 2017, Eur. J. Oper. Res..

[32]  Elias Mossialos,et al.  Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. , 2016, Health policy.

[33]  Xu Chen,et al.  Option pricing and coordination in the fresh produce supply chain with portfolio contracts , 2016, Annals of Operations Research.

[34]  A. Haycox,et al.  Insight into recent reforms and initiatives in Austria: implications for key stakeholders , 2008, Expert review of pharmacoeconomics & outcomes research.

[35]  Habib Chabchoub,et al.  A combined approach for supply chain risk management: description and application to a real hospital pharmaceutical case study , 2014 .

[36]  P. Danzon,et al.  PHARMACEUTICAL PRICING IN EMERGING MARKETS: EFFECTS OF INCOME, COMPETITION, AND PROCUREMENT , 2011, Health economics.

[37]  Hing Kai Chan,et al.  Manufacturer and retailer coordination for environmental and economic competitiveness: A power perspective , 2017 .

[38]  Katherinne Salas Navarro,et al.  A three layer supply chain model with multiple suppliers, manufacturers and retailers for multiple items , 2014, Appl. Math. Comput..

[39]  Zhu Chen,et al.  Launch of the health-care reform plan in China , 2009, The Lancet.

[40]  Alessandro Minichilli,et al.  Integrating Agency and Resource Dependence Theory: Firm Profitability, Industry Regulation, and Board Tasks Performance , 2013 .

[41]  Anna Nagurney,et al.  Pharmaceutical Supply Chain Networks with Outsourcing Under Price and Quality Competition , 2013, Int. Trans. Oper. Res..

[42]  Sujuan Wang,et al.  Contract type and decision right of sales promotion in supply chain management with a capital constrained retailer , 2015, Eur. J. Oper. Res..

[43]  Xue Qiao,et al.  Effects of pharmaceutical price regulation: China's evidence between 1997 and 2008 , 2015 .

[44]  Nina Pavcnik.  Do pharmaceutical prices respond to potential patient out-of-pocket expenses? , 2002 .

[45]  M. Ekelund,et al.  Pharmaceutical Pricing in a Regulated Market , 2003, Review of Economics and Statistics.

[46]  Amir H. Masoumi,et al.  A Supply Chain Generalized Network Oligopoly Model for Pharmaceuticals under Brand Differentiation and Perishability , 2012 .

[47]  Ettore Settanni,et al.  Pharmaceutical supply chain models: A synthesis from a systems view of operations research , 2017 .

[48]  Joel Lexchin,et al.  The cost of drug development: a systematic review. , 2011, Health policy.

[49]  Adrian Towse,et al.  Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context , 2012, Health economics.

[50]  Sandro Zolezzi,et al.  Electronic tendering of pharmaceuticals and medical devices in Chile , 2015 .

[51]  Qiang Liu,et al.  An Empirical Model of Drug Detailing: Dynamic Competition and Policy Implications , 2015, Manag. Sci..

[52]  Xu Chen,et al.  The impact of power structure on the retail service supply chain with an O2O mixed channel , 2016, J. Oper. Res. Soc..

[53]  B. Jullien,et al.  Retail price regulation and innovation: reference pricing in the pharmaceutical industry. , 2009, Journal of health economics.

[54]  V. Bhakoo,et al.  Collaborative implementation of e‐business processes within the health‐care supply chain: the Monash Pharmacy Project , 2011 .

[55]  Kurt R. Brekke,et al.  Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? , 2007, SSRN Electronic Journal.